Literature DB >> 30775826

Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Peter G Hawkins1, Michelle L Mierzwa1, Emily Bellile2, William C Jackson1, Kelly M Malloy3, Steven B Chinn3, Matthew E Spector3, Andrew G Shuman3, Chaz L Stucken3, Scott A McLean3, Carol R Bradford3, Mark E Prince3, Thomas E Carey3,4, Francis P Worden5, Paul L Swiecicki5, Jeremy M G Taylor2, Gregory T Wolf3, Avraham Eisbruch1, Keith A Casper3.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the AJCC eighth edition clinical staging system for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma and to further understand how clinical stage and smoking history affect oncologic outcomes. The purpose of this study was to present the understanding of how clinical stage and smoking history affect oncologic outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (SCC) is critical for selecting patients for treatment deintensification.
METHODS: Kaplan-Meier and Cox regression were used to evaluate overall survival (OS), locoregional recurrence-free survival (LRFS), and distant recurrence-free survival (DRFS). Concordance statistics (C-indices) were used to compare discriminating ability.
RESULTS: The OS and DRFS but not LRFS were significantly distributed using the American Joint Committee on Cancer (AJCC) seventh and eighth editions criteria. The C-indices for OS, LRFS, and DRFS were 0.57, 0.54, and 0.60, respectively, using the AJCC seventh edition, and 0.63, 0.53, and 0.65, respectively, using the AJCC eighth edition. On multivariate analysis, 1 + pack-year smoking history correlated with OS (hazard ratio [HR] 1.96; 95% confidence interval [CI] 1.2-3.1; P < .01) but not LRFS or DRFS.
CONCLUSION: These results support implementation of the AJCC eighth edition for HPV-associated oropharyngeal SCC. Clinical stage may be more important than smoking history in selection for deintensification.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  American Joint Committee on Cancer; clinical staging; human papillomavirus (HPV); oropharyngeal squamous cell carcinoma; smoking

Mesh:

Year:  2019        PMID: 30775826      PMCID: PMC6420360          DOI: 10.1002/hed.25336

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.821


  21 in total

1.  Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation.

Authors:  Brian O'Sullivan; Shao Hui Huang; Bayardo Perez-Ordonez; Christine Massey; Lillian L Siu; Ilan Weinreb; Andrew Hope; John Kim; Andrew J Bayley; Bernard Cummings; Jolie Ringash; Laura A Dawson; B C John Cho; Eric Chen; Jonathan Irish; Ralph W Gilbert; Angela Hui; Fei-Fei Liu; Helen Zhao; John N Waldron; Wei Xu
Journal:  Radiother Oncol       Date:  2012-03-10       Impact factor: 6.280

2.  Staging and treatment of oropharyngeal cancer in the human papillomavirus era.

Authors:  Matthew J Ward; Toby Mellows; Scott Harris; Andrew Webb; Nimesh N Patel; Hugh J Cox; Kim Piper; Christian H Ottensmeier; Gareth J Thomas; Emma V King
Journal:  Head Neck       Date:  2014-07-12       Impact factor: 3.147

3.  Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer.

Authors:  Shao Hui Huang; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Hope; Christine Massey; John N Waldron; John Kim; Andrew J Bayley; Bernard Cummings; B C John Cho; Jolie Ringash; Laura A Dawson; Lillian L Siu; Eric Chen; Jonathan Irish; Patrick Gullane; Angela Hui; Fei-Fei Liu; Xiaowei Shen; Wei Xu; Brian O'Sullivan
Journal:  Oral Oncol       Date:  2012-08-20       Impact factor: 5.337

4.  An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair.

Authors:  Kristina R Dahlstrom; Gabriel Calzada; Jennifer D Hanby; Adam S Garden; Bonnie S Glisson; Guojun Li; Dianna B Roberts; Randal S Weber; Erich M Sturgis
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

5.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.

Authors:  Brian O'Sullivan; Shao Hui Huang; Jie Su; Adam S Garden; Erich M Sturgis; Kristina Dahlstrom; Nancy Lee; Nadeem Riaz; Xin Pei; Shlomo A Koyfman; David Adelstein; Brian B Burkey; Jeppe Friborg; Claus A Kristensen; Anita B Gothelf; Frank Hoebers; Bernd Kremer; Ernst-Jan Speel; Daniel W Bowles; David Raben; Sana D Karam; Eugene Yu; Wei Xu
Journal:  Lancet Oncol       Date:  2016-02-27       Impact factor: 41.316

6.  Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.

Authors:  Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

7.  Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.

Authors:  Shao Hui Huang; Bayardo Perez-Ordonez; Fei-Fei Liu; John Waldron; Jolie Ringash; Jonathan Irish; Bernard Cummings; Lillian L Siu; John Kim; Ilan Weinreb; Andrew Hope; Patrick Gullane; Dale Brown; Willa Shi; Brian O'Sullivan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

8.  Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer.

Authors:  Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

9.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Authors:  Shanthi Marur; Shuli Li; Anthony J Cmelak; Maura L Gillison; Weiqiang J Zhao; Robert L Ferris; William H Westra; Jill Gilbert; Julie E Bauman; Lynne I Wagner; David R Trevarthen; Jahagirdar Balkrishna; Barbara A Murphy; Nishant Agrawal; A Dimitrios Colevas; Christine H Chung; Barbara Burtness
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

10.  De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.

Authors:  Liam Masterson; Daniel Moualed; Zi Wei Liu; James E F Howard; Raghav C Dwivedi; James R Tysome; Richard Benson; Jane C Sterling; Holger Sudhoff; Piyush Jani; Peter K C Goon
Journal:  Eur J Cancer       Date:  2014-08-01       Impact factor: 9.162

View more
  8 in total

1.  Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin.

Authors:  Paul L Swiecicki; Pin Li; Emily Bellile; Chaz Stucken; Kelly Malloy; Andrew Shuman; Matthew E Spector; Steven Chinn; Keith Casper; Scott McLean; Jeffery Moyer; Douglas Chepeha; Gregory T Wolf; Mark Prince; Carol Bradford; Mukesh Nyati; Avraham Eisbruch; Francis P Worden; Shruti Jolly; Michelle Mierzwa
Journal:  Head Neck       Date:  2020-01-27       Impact factor: 3.147

2.  Impact of Smoking on the Survival of Patients With High-risk HPV-positive HNSCC: A Meta-analysis.

Authors:  Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes.

Authors:  Stephanie Y Chen; Aisling Last; Abhinav Ettyreddy; Dorina Kallogjeri; Benjamin Wahle; Smrithi Chidambaram; Angela Mazul; Wade Thorstad; Ryan S Jackson; Jose P Zevallos; Patrik Pipkorn
Journal:  Am J Otolaryngol       Date:  2021-01-13       Impact factor: 1.808

Review 4.  Statistical fundamentals on cancer research for clinicians: Working with your statisticians.

Authors:  Wei Xu; Shao Hui Huang; Jie Su; Shivakumar Gudi; Brian O'Sullivan
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-16

5.  Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel.

Authors:  Shao Hui Huang; Shlomo Koyfman; Brian O'Sullivan
Journal:  Oncologist       Date:  2022-02-03

6.  Additional parameters to improve the prognostic value of the 8th edition of the UICC classification for human papillomavirus-related oropharyngeal tumors.

Authors:  Jos M J A A Straetmans; Marijn Stuut; Martin Lacko; Frank Hoebers; Ernst-Jan M Speel; Bernd Kremer
Journal:  Head Neck       Date:  2022-05-17       Impact factor: 3.821

7.  Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16- High Risk Head and Neck Cancer.

Authors:  Yue Cao; Madhava Aryal; Pin Li; Choonik Lee; Matthew Schipper; Peter G Hawkins; Christina Chapman; Dawn Owen; Aleksandar F Dragovic; Paul Swiecicki; Keith Casper; Francis Worden; Theodore S Lawrence; Avraham Eisbruch; Michelle Mierzwa
Journal:  Front Oncol       Date:  2019-11-14       Impact factor: 6.244

8.  Development and Assessment of a Model for Predicting Individualized Outcomes in Patients With Oropharyngeal Cancer.

Authors:  Lauren J Beesley; Andrew G Shuman; Michelle L Mierzwa; Emily L Bellile; Benjamin S Rosen; Keith A Casper; Mohannad Ibrahim; Sarah M Dermody; Gregory T Wolf; Steven B Chinn; Matthew E Spector; Robert J Baatenburg de Jong; Emilie A C Dronkers; Jeremy M G Taylor
Journal:  JAMA Netw Open       Date:  2021-08-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.